Starling Oncology Institute Inc (STLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Sales | 64,977 | 60,921 | 55,161 | 52,304 | 52,275 |
| Cost of Goods | 51,977 | 49,779 | 42,839 | 43,971 | 40,852 |
| Gross Profit | 13,000 | 11,142 | 12,322 | 8,333 | 11,423 |
| Operating Expenses | 34,074 | 30,225 | 31,632 | 50,136 | 14,432 |
| Operating Income | -20,097 | -18,304 | -18,471 | -40,832 | -2,157 |
| Interest Expense | 1,497 | 61 | 74 | 60 | 78 |
| Other Income | 18,896 | 12,880 | 38,011 | 28,268 | 54 |
| Pre-tax Income | -2,698 | -5,485 | 19,466 | -12,624 | -2,181 |
| Income Tax | -24 | -32 | 180 | -2,468 | 799 |
| Net Income Continuous | -2,674 | -5,453 | 19,286 | -10,156 | -2,980 |
| Net Income | $-2,674 | $-5,453 | $19,286 | $-10,156 | $-2,980 |
| EPS Basic Total Ops | -0.03 | -0.06 | 0.22 | -0.14 | -0.05 |
| EPS Basic Continuous Ops | -0.04 | -0.07 | 0.26 | -0.15 | -0.05 |
| EPS Diluted Total Ops | -0.17 | -0.06 | 0.21 | -0.14 | -0.05 |
| EPS Diluted Continuous Ops | -0.03 | -0.07 | 0.25 | -0.15 | -0.05 |
| EBITDA(a) | $-18,100 | $-17,206 | $-17,484 | $-39,912 | $-1,289 |